Quick Takeaways: Why It Matters? By pairing patented ProLong Technology, which bonds to gums and slowly releases active ingredients to control plaque and tartar, with a catnip flavor and “twist-and-lick” format, Tevra is positioning Vetality Brush Free Twist + Lick as a flagship product in...
Quick Takeaways: Why It Matters? SilverCape’s lower $3.00/share proposal keeps PetMed Express in play as a potential takeout target, but the reduced price weakens the bid’s attractiveness and gives the board room to push for better terms or shop alternatives. Market-wise, it signals that a...
Quick Takeaways: Why It Matters? Marley Health’s launch pushes veterinary care toward continuous, data-driven monitoring by combining a smart collar with vet and owner tools that track clinically meaningful biomarkers like gait, posture, resting heart rate, and respiratory rate between vis...
Featured Article Cover Story Regulatory Updates Research Updates Product Launch Retail expansion Dechra Opens Global Headquarters in Boston Corporate update Dechra has opened its new global headquarters in Boston, strengthening its innovation footprint while supporting community programs t...
Quick Takeaways: Why It Matters? Full FDA approval for Laverdia transforms it from a conditionally approved option into the first fully approved oral, at‑home standard therapy for canine lymphoma, which should significantly boost veterinarian confidence and utilization via Dechra’s nationa...
Quick Takeaways: Why It Matters? Wuffes’ PetSmart rollout is a big distribution milestone that moves it from DTC success into mainstream retail scale, giving the brand national shelf visibility, stronger consumer trust, and access to PetSmart’s 1,300+ U.S. stores plus its e-commerce traffi...
Quick Takeaways: Why It Matters? Dechra’s Boston HQ move and community-facing strategy signal how veterinary pharma is increasingly aligning with mainstream human health and life sciences ecosystems, not just traditional animal-health hubs, which could intensify competition for talent, par...
Quick Takeaways: Why It Matters? Jaguar’s NADA submission is a meaningful de-risking step for Canalevia-CA1, because full FDA approval would likely expand its commercial credibility beyond conditional use and make it easier to gain adoption in veterinary onc...
Quick Takeaways: Why It Matters? CompanAIn’s Veterinary Portal broadens its AI pet-wellness platform from owner-facing tools into a shared clinical workflow, which could make the product stickier for clinics and more valuable for longitudinal care. By giving vets ...
The US FDA’s 2025 animal health approvals highlight a transformative year for veterinary medicine, with major advances spanning companion animal therapeutics, livestock productivity, poultry health, parasitic disease management, diagnostics, oncology, and genetic innovation. The latest wav...
